The ETH and ISB Zurich announced completion of the first stage of the two-year project.

Agilent, ISB and ETH Zurich enter second phase of mapping complete individual proteome Ninth Annual World Conference of the Individual Proteome Organization – – Agilent Technology Inc. today announced that its collaboration with the Institute for Systems Biology and the Swiss Federal government Institute of Technology for the mapping of the entire human being proteome by mass spectrometry is definitely entering its second stage . 20, the ETH and ISB Zurich announced completion of the first stage of the two-year project, including generating gold-regular reference mass spectra for each of 20,300 genes annotated as protein-encoding in the human genome currently.

Abhijeet J. Lele, Controlling Director of Investor Development Capital, added, Agile is certainly making important progress in its clinical advancement programs, with not only AG200-15, however in its pipeline products like the levonorgestrel-just patch also, AG1000, for females who are breastfeeding or cannot use estrogen-based contraceptives. We anticipate supporting the company’s development, and bringing innovative items to the women’s health market to fill a compelling unmet want. According to market research conducted with respect to Agile with 105 OB/GYN doctors who are significant prescribers of contraception, 89 % said they might be likely to prescribe AG200-15. Nearly half said they might prescribe it upon acceptance immediately, demonstrating that doctors perceive a large need among their patients for the convenience and capability of Agile’s low-dose, weekly contraceptive patch.